Innate pharma reports higher annual revenue in 2011

• Revenue of 11.7 million euros including payments from partners Bristol-Myers Squibb and Novo Nordisk A/S as well as research tax credit
  
• Strong cash position with 46.6 million euros in cash, cash equivalents and current financial instruments as at December 31, 2011
  
  (IFRS unaudited provisional data)

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue and other income of 11.7 million euros for the year 2011, compared to 4.3 million euros in 2010.